Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chiome Bioscience Inc.
  6. News
  7. Summary
    4583   JP3205350006

CHIOME BIOSCIENCE INC.

(4583)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Chiome Bioscience : Supplement Documents for Financial Results Q1 FY12/21

05/14/2021 | 11:25am EDT

Supplement Documents for Financial Results Q1 FY12/21

May 14, 2021

To accelerate drug discovery and development of mAb for therapeutics to overcome current medical unmet-needs

Chiome Bioscience Inc.

Agenda

1.Overview of Q1 FY12/21 "Financial results"

2.Overview of Q1 FY12/21 "Operation highlights"

Appendix.

Corporate information

Pipeline information

2

Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved.

Overview of

Q1 FY12/21 "Financial results"

Copyright © 2017 Chiome Bioscience Inc. All Rights Reserved.

3

Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved.

Financial results: Profit and Loss

(JPY in millions)

Q1 FY2020

Q1 FY2021

Increase

(decrease)

Net sales

90

246

155

Drug Discovery &

103

103

Development

Drug Discovery

89

143

53

• Growth in business with domestic

Support

pharmaceutical companies

COS/SGA

517

401

(115)

R&D Expense

342

216

(126)

• Decrease in the cost of study drug

manufacturing and CRO in CBA-1205

program

Other costs

174

185

10

• Up in material costs due to increased

business transactions

Operating Loss

(426)

(155)

271

Ordinary Loss

(424)

(149)

275

Net Loss

(425)

(160)

264

Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved.

4

Financial results: Balance Sheet

(JPY in millions)

As of Dec. 31, 2020

As of Mar. 31, 2021

Current assets

3,248

3,293

Cash on hand in banks)

2,686

2,580

(Other current assets)

562

713

Non-current assets

246

243

Total assets

3,494

3,537

Current Liabilities

342

377

Non-current liabilities

41

41

Total liabilities

384

419

Total net assets

3,109

3,117

Total liabilities and net assets

3,494

3,537

5

Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved.

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Chiome Bioscience Inc. published this content on 14 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 May 2021 15:24:05 UTC.


ę Publicnow 2021
All news about CHIOME BIOSCIENCE INC.
08/13CHIOME BIOSCIENCE : Supplement Documents for Financial Results Q2 FY12/21
PU
08/13CHIOME BIOSCIENCE : Non-Consolidated Financial Results (Japanese GAAP) for the Six Months ..
PU
08/13Chiome Bioscience Inc. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
05/14CHIOME BIOSCIENCE : Termination of Collaborative Development License and Exclusive Option ..
PU
05/14CHIOME BIOSCIENCE : Non-Consolidated Financial Results (Japanese GAAP) for the Three Month..
PU
05/14CHIOME BIOSCIENCE : Supplement Documents for Financial Results Q1 FY12/21
PU
05/14CHIOME BIOSCIENCE : Collaborative Research Agreement with Mologic Ltd. for antibody discov..
PU
05/14Chiome Bioscience Inc. Announces Collaborative Research Agreement with Mologic Ltd. for..
CI
05/14Chiome Bioscience Inc. Announces Non-Consolidated Earnings Results for the Three Months..
CI
05/14Chiome Bioscience Inc. Announces Termination of Collaborative Development License and E..
CI
More news
Financials
Sales 2020 600 M 5,42 M 5,42 M
Net income 2020 -1 400 M -12,6 M -12,6 M
Net Debt 2020 - - -
P/E ratio 2020 -6,19x
Yield 2020 -
Capitalization 9 632 M 87,0 M 87,0 M
Capi. / Sales 2020 16,1x
Capi. / Sales 2021 13,2x
Nbr of Employees 53
Free-Float 94,2%
Chart CHIOME BIOSCIENCE INC.
Duration : Period :
Chiome Bioscience Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHIOME BIOSCIENCE INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 239,00 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Shigeru Kobayashi President & Representative Director
Akiyuki Furuya Independent Outside Director
Haruhisa Kubota Independent Outside Director
Arihiko Bijohira Director & Manager-Corporate Planning Office
Sector and Competitors
1st jan.Capi. (M$)
CHIOME BIOSCIENCE INC.28.49%87
MODERNA, INC.311.74%183 498
LONZA GROUP AG33.58%61 085
IQVIA HOLDINGS INC.46.01%50 254
CELLTRION, INC.-23.54%33 124
SEAGEN INC.-7.88%30 241